

# Riccardo Sibilano, M.Sc., Ph.D.

## Oncology Medical Lead

Immunologist with **15 years** of postgraduate experience in research and medical affairs.

With a proven track record in target identification and discovery, drug development, and US and global medical affairs, I excel at building partnerships, fostering scientific collaboration, and effectively engaging stakeholders. I am passionate about advancing the fields of immunology and oncology and driving innovations that profoundly impact patients' lives.

### 1) CAREER MILESTONES

---

- Experience launching several medical assets in oncology
- Global and US Medical experience
- Collaborated with external stakeholders to evaluate and initiate over 100 scientific studies collaborations
- Reviewed and assessed over 10 oncology assets at various stages of development
- Transitioned two molecules to First-in-Human/Ph1 studies

### 2) EDUCATION

---

**Stanford, School of Medicine**, Stanford, CA, USA – *Postdoc* (Immunology and Pathology)

**University of Udine, School of Medicine** (ranked no. 1 in Italy in 2010), Udine, Italy – *Ph.D.* **2008-2010**

Biomedical and Biotechnological Sciences (Immunology)

**University of Trieste**, Trieste, Italy – *M. Sc.* (with honors) Functional Genomics **2005-2007**

**University of Bari**, Bari, Italy – *B. Sc.* (with honors) Cellular and Molecular Biology **2002-2005**

### 3) EMPLOYMENT

---

**Oncology Medical Affairs Strategy – oncology and biomarkers** **(7 years)**

**Independent Medical Affairs Consultant** **2025-present**

Consulting on medical strategies, including developing evidence generation plans, medical communications, engaging patient advocates and KOLs for Oncology biotech

**Sanofi Genzyme** – SF Bay Area, CA, USA; reporting to Oncology Head

*US Medical Lead (USMAL) - Medical Affairs, Oncology* **2023-present**

*Medical Director - Medical Affairs, Oncology and Pipeline* **2020-2022**

#### **i) Oncology and Precision Medicine Medical Affairs Strategy**

**a) Solid tumors:** US pre-launch and launch activities for cemiplimab/Libtayo (PD-1 inhibitor) and tusamitamab ravtansine (a-CEACAM5-DM4; US and global post market medical plans for Jevtana/Cabazitazetel (prostate)

**b) Pipeline strategy (solid and hematologic tumors):** Medical plans for early pipeline molecules in Phase 2, including combination studies with Sanofi's cemiplimab and other pipeline assets

*Applies to all the above:*

- Develop a strong network of KOLs
- Strategize and execute stakeholder engagement and collaboration in both academic and community settings
- Map and engage patient organizations and advocates in collaboration with the appropriate company teams
- Procure and manage an average budget of USD 3M annually across assets and indications
- Establish, coordinate, and support the field medical (MSL) strategy, including data dissemination, outreach, insight generation for other departments and senior leadership, and initial outreach for collaborations
- Develop ad boards and steering committee strategies
- Formulate a US strategy for data communication and interpretation
- Contribute to trial enrollment strategies and patient engagement in clinical trials
- Establish external scientific collaborations, including investigator-sponsored trials
- Contribute to evidence generation strategy and execution, including clinical, translational, biomarker, and real-world evidence (RWE) studies
- Manage direct reports.

*Clinical and Biomarker study design:*

- Co-authored over 10 protocols and proposals for Phase IV studies, biomarkers, and translational studies for the TAs

listed above

- Reviewed more than 50 clinical study protocols for investigator-sponsored trials (Phase I/II/III)

**Exelixis – Alameda, CA, USA; reporting to Exec. Dir., Med. Affairs**

**2019-2020**

*Global Medical Affairs, Associate Director (cabozantinib – c-Met/VEGFR2/AXL/RET TKI in **GU cancers**)*

- Launched cabozantinib/CABOMETYX for 1L advanced kidney cancer in combination with nivolumab
- Support and develop medical, evidence-generation, and communication strategies for cabozantinib while managing an average annual budget of USD 3M across indications
- Strategize and execute KOL engagement, oversee ISS/Grant/global research management
- Develop a scientific communication strategy that includes digital health, websites, content, conferences, publications, and posters

**Pharma Oncology R&D – lung and skin immunology, PD-1 inhibitors and immune checkpoints (4 years)**

**Boehringer Ingelheim – Ridgefield, CT, USA**

**2017-2019**

*Principal Scientist/Associate Director, Immune Modulation, Research and S&E Group Lead*

- R&D group leader, managed up to 8 total reports (M.Sc. and Ph.D. level)
- Identified and conducted due diligence on several external assets for immuno-oncology
- Pre-clinical lead for FIH/Ph1 development of a novel checkpoint inhibitor and combination studies with PD-1 inhibitors.

**Pfizer – South San Francisco, CA, USA**

**2016-2017**

*Senior Scientist – Lung/skin inflammation and cancer immunology*

- R&D group leader, managing 2-3 direct reports
- Validated and developed antibody-based therapeutics for inflammatory disease indications (TNF(R) family – OX40(L), LIGHT for skin and respiratory applications)
- Project lead for a BCMA-CD3 bi-specific antibody

**Academia R&D – lung and skin immunology**

**(6 years)**

**Stanford University School of Medicine, Stanford, CA, USA – Department of Pathology**

**2015-2016**

*Assistant Professor, Principal Investigator*

- Advanced the scientific understanding and etiology of chronic inflammatory diseases through TNF(R) signaling (including OX40(L), LT-betaR, LIGHT, HVEM, etc.)
- Secured and allocated resources for a competitive early-stage NIH grant (see below)
- Awarded an early career NIH grant (K99/R00, NIAID - total USD 550K for 4 years)
- Published six high-impact factor immunology manuscripts (Nature Communications, Journal of Clinical Investigation, and Journal of Allergy and Clinical Immunology)

*Postdoctoral Fellow – Department of Pathology (lab of Dr. Stephen J. Galli)*

**2012-2015**

- Studied the pathogenesis of severe airway inflammation
- Awarded with a Spectrum Child Health Postdoctoral Fellowship Award from the Stanford Lucile Packard Children's Hospital, Stanford, CA (USD 50K)
- Five manuscripts accepted for publication

**University of Udine School of Medicine, Udine, Italy - Department of Immunology**

**2010-2012**

*Postdoctoral Fellow – Department of Immunology*

- Studied the activation of mast cells in response to airway pollutants through the aryl hydrocarbon receptor (AhR)
- Recipient of a post-doctoral fellowship from the Italian Cancer Association (AIRC), Milan, Italy (USD 15K)
- Five publications in top-impact-factor allergy journals and high-impact-factor immunology journals

#### **4) PEER-REVIEWED PUBLICATIONS (total 25, not including manuscripts under review)**

The following list includes first- and co-authored publications in top-tier clinical and immunology journals.

<https://www.ncbi.nlm.nih.gov/sites/myncbi/10cJINicqmyks/bibliography/44166069/public/?sort=date&direction=descending>

#### **5) ADDITIONAL INFORMATION, SKILLS, AND INTERESTS**

- Dual citizenship: Italy, USA
- Spoken languages: English, Spanish, Italian (native)
- More than 20 invited oral communications and over 50 posters, scientific abstracts, and articles (2010 – present)
- Peer reviewer for multiple scientific journals (2012-present)
- Group leader/manager (2015-present); student supervisor (2008-2012); classroom teacher (2008-2010)